Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term ...
SHANGHAI and CAMBRIDGE, Mass. , Jan. 15, 2025 /PRNewswire/ -- Orna Therapeutics, Inc. ("Orna") and Shanghai Simnova Biotech Co., Ltd. ("Simnova") are pleased to announce the expansion of their ...
(RTTNews) - Merck (MRK), and Orna Therapeutics on Tuesday announced partnership to advance Orna's circular RNA technology. As per the deal, Orna will receive an upfront payment of $150 million, and ...
Anti-CD19 panCARTM program (ORN-252) demonstrated robust B cell depletion with significant reduction in anti-dsDNA titers in humanized lupus model Anti-BCMA panCARTM program showed robust and durable ...
Merck and Cambridge, Mass.-based Orna Therapeutics announced a collaboration Aug. 16 to develop and commercialize multiple programs, including vaccines and therapeutics in infectious disease and ...
This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. Eli Lilly will pay up to $2.4 billion to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results